71 results on '"Burdelski C"'
Search Results
2. Auswirkung des CytoSorb-Adsorbers auf hämodynamische und immunologische Parameter bei kritisch kranken Patienten mit COVID-19 – Adjuvant therapy witch CYTOSorb in COVID-19 – CytoCOV-19
- Author
-
Jarczak, D, additional, Roedl, K, additional, Fischer, M, additional, de Heer, G, additional, Burdelski, C, additional, Frings, D, additional, Sensen, B, additional, Boenisch, O, additional, Tariparast, A, additional, Kluge, S, additional, and Nierhaus, A, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Leberdysfunktion bei kritisch kranken mit COVID-19: Vorkommen und Outcome
- Author
-
Roedl, K, additional, Jarczak, D, additional, Drolz, A, additional, Wichmann, D, additional, Boenisch, O, additional, de Heer, G, additional, Burdelski, C, additional, Frings, D, additional, Sensen, B, additional, Nierhaus, A, additional, Lütgehetmann, M, additional, Kluge, S, additional, and Fuhrmann, V, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Arterial en bloc resection for pancreatic carcinoma
- Author
-
Bockhorn, M., Burdelski, C., Bogoevski, D., Sgourakis, G., Yekebas, E. F., and Izbicki, J. R.
- Published
- 2011
5. Development of an enzyme-linked immunosorbent assay specifically detecting antipolysaccharide intercellular-adhesin antibodies: P1499
- Author
-
Rohde, H., Klettke, J., Siemssen, N., Frommelt, L., Horstkotte, M. A., Burdelski, C., Knobloch, J. K.-M., and Mack, D.
- Published
- 2005
6. Resektion von kleinen nicht-funktionellen neuroendokrinen Tumoren des Pankreas: Ist die Größe ein relevantes Entscheidungskriterium?
- Author
-
Burdelski, C, additional, Vashist, Y, additional, Perez, D, additional, Lohse, A, additional, Izbicki, J, additional, and Schrader, J, additional
- Published
- 2017
- Full Text
- View/download PDF
7. Enterale Ernährung in Bauchlage bei Patienten mit ARDS
- Author
-
Burdelski, C, additional, de Heer, G, additional, Backer, E, additional, and Kluge, S, additional
- Published
- 2017
- Full Text
- View/download PDF
8. Tumour size is not a reliable criterion for management of patients with Non-secreting pancreatic neuroendocrine tumours: results of a large, multi-centre, operative cohort
- Author
-
Mills, Logan, primary, Drymousis, Panagiotis, additional, Vashist, J, additional, Burdelski, C, additional, Prachalias, Andreas, additional, Srinivasan, Parthi, additional, Menon, Krishna, additional, Khan, Saboor, additional, Cave, Judith, additional, Armstrong, Thomas, additional, Weickert, MO, additional, Frilling, Andreja, additional, Ramage, JK, additional, and Srirajaskanthan, Raj, additional
- Published
- 2016
- Full Text
- View/download PDF
9. Nicht-intentionelle R2 Resektionen in Patienten mit Pankreaskarzinom - ein onkologisches Desaster?
- Author
-
Bockhorn, M., Cataldegirmen, G., Burdelski, C., Kutup, A., König, A., Vashist, Y., Marx, A., Izbicki, J.R., and Yekebas, E.
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Einleitung: Nach wie vor wird die Frage nach dem Benefit der nicht-intentionalen R2 Resektion für Patienten mit Pankreaskarzinom kontrovers diskutiert. Ziel unserer Studie war die Analyse unseres Patientenguts hinsichtlich klinischer und onkologischer Parameter. Spezielles Augenmerk wurde dabei[for full text, please go to the a.m. URL], 126. Kongress der Deutschen Gesellschaft für Chirurgie
- Published
- 2009
- Full Text
- View/download PDF
10. Stellenwert der Pankreasresektion mit arterieller en-bloc Gefäßresektion beim lokal fortgeschrittenen Pankreaskarzinom
- Author
-
Bockhorn, M, Burdelski, C, Vashist, Y, Kutup, A, König, A, Cataldegirmen, G, Marx, A, Izbicki, JR, and Yekebas, E
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Einleitung: Im Gegensatz zur umschriebenen Tumorinfiltration in die V. mesenterica sup./ V. portae, bei denen die Resektion deutliche Überlebensvorteile bietet, ist das Vorgehen beim lokal fortgeschrittenen Pankreaskarzinom mit Infiltration des Tr. coeliacus und seiner Äste oder der A.[for full text, please go to the a.m. URL], 126. Kongress der Deutschen Gesellschaft für Chirurgie
- Published
- 2009
- Full Text
- View/download PDF
11. Multiviszerale Resektionen zur Therapie des lokal fortgeschrittenen Pankreaskarzinoms
- Author
-
Burdelski, C, Reeh, M, Bogoevski, D, Gebauer, F, Tachezy, M, Vashist, YK, Cataldegirmen, G, Yekebas, E, Izbicki, JR, Bockhorn, M, Burdelski, C, Reeh, M, Bogoevski, D, Gebauer, F, Tachezy, M, Vashist, YK, Cataldegirmen, G, Yekebas, E, Izbicki, JR, and Bockhorn, M
- Published
- 2012
12. Nicht-intentionelle R2 Resektionen in Patienten mit Pankreaskarzinom - ein onkologisches Desaster?
- Author
-
Bockhorn, M, Cataldegirmen, G, Burdelski, C, Kutup, A, König, A, Vashist, Y, Marx, A, Izbicki, JR, Yekebas, E, Bockhorn, M, Cataldegirmen, G, Burdelski, C, Kutup, A, König, A, Vashist, Y, Marx, A, Izbicki, JR, and Yekebas, E
- Published
- 2009
13. Arterial en bloc resection for pancreatic carcinoma
- Author
-
Bockhorn, M, primary, Burdelski, C, additional, Bogoevski, D, additional, Sgourakis, G, additional, Yekebas, E F, additional, and Izbicki, J R, additional
- Published
- 2010
- Full Text
- View/download PDF
14. Perivascular epitheloid cell tumour (PEComa) of the retroperitoneum – a rare tumor with uncertain malignant behaviour: a case report
- Author
-
Koenig Alexandra M, Quaas Alexander, Ries Thorsten, Yekebas Emre F, Gawad Karim A, Vashist Yogesh K, Burdelski Christoph, Mann Oliver, Izbicki Jakob R, and Erbersdobler Andreas
- Subjects
Medicine - Abstract
Abstract Introduction Perivascular epitheloid cell tumours are rare mesenchymal neoplasms characterized by a proliferation of perivascular cells with an epitheloid phenotype and expression of myomelanocytic markers. Case presentation Here we present the case of a cystic perivascular epitheloid cell tumour of the retroperitoneum associated with multifocal lung lesions. A 27-year-old woman underwent laparotomy to remove a 10 × 6 × 4 cm sized retroperitoneal mass. The resected specimen was subjected to frozen and permanent histological sections with conventional and immunohistochemical stains, including antibodies against HMB45. The tumour displayed the typical morphological and immunohistochemical features of a perivascular epitheloid cell tumour. Focal necrosis and a proliferative index of 10% suggested a malignant potential. Moreover, postoperative computed tomography scans demonstrated multiple lung lesions, which were radiologically interpreted as being most likely compatible with lymphangioleiomyomatosis. Conclusion Since lymphangioleiomyomatosis, an otherwise benign condition, belongs to the family of perivascular epitheloid cell tumours, it cannot be excluded that the lung lesions in this case in fact represent metastases from the retroperitoneal perivascular epitheloid cell tumour rather than independent neoplasms. More experience with this new and unusual tumour entity is clearly needed in order to define reliable criteria for benign or malignant behaviour.
- Published
- 2009
- Full Text
- View/download PDF
15. Association Between Dyscapnia, Ventilatory Variables, and Mortality in Patients With Acute Respiratory Distress Syndrome-A Retrospective Cohort Study.
- Author
-
Braunsteiner J, Castro L, Wiessner C, Grensemann J, Schroeder M, Burdelski C, Sensen B, Kluge S, and Fischer M
- Abstract
Background: This study aimed to investigate the associations between dyscapnia, ventilatory variables, and mortality. We hypothesized that the association between mechanical power or ventilatory ratio and survival is mediated by dyscapnia. Methods: Patients with moderate or severe acute respiratory distress syndrome (ARDS), who received mechanical ventilation within the first 48 h after admission to the intensive care unit for at least 48 h, were included in this retrospective single-center study. Values of arterial carbon dioxide (PaCO
2 ) were categorized into "hypercapnia" (PaCO2 ≥ 50 mm Hg), "normocapnia" (PaCO2 36-49 mmHg), and "hypocapnia" (PaCO2 ≤ 35 mm Hg). We used path analyses to assess the associations between ventilatory variables (mechanical power and ventilatory ratio) and mortality, where hypocapnia or hypercapnia were included as mediating variables. Results: Between December 2017 and April 2021, 435 patients were included. While there was a significant association between mechanical power and hypercapnia (BEM = 0.24 [95% CI: 0.15; 0.34], P < .01), there was no significant association between mechanical power or hypercapnia and ICU mortality. The association between mechanical power and intensive care unit (ICU) mortality was fully mediated by hypocapnia (BEM = -0.10 [95% CI: -0.19; 0.00], P = .05; BMO = 0.38 [95% CI: 0.13; 0.63], P < .01). Ventilatory ratio was significantly associated with hypercapnia (B = 0.23 [95% CI: 0.14; 0.32], P < .01). There was no significant association between ventilatory ratio, hypercapnia, and mortality. There was a significant effect of ventilatory ratio on mortality, which was fully mediated by hypocapnia (BEM = -0.14 [95% CI: -0.24; -0.05], P < .01; BMO = 0.37 [95% CI: 0.12; 0.62], P < .01). Conclusion: In mechanically ventilated patients with moderate or severe ARDS, the association between mechanical power and mortality was fully mediated by hypocapnia. Likewise, there was a mediating effect of hypocapnia on the association between ventilatory ratio and ICU mortality. Our results indicate that the debate on dyscapnia and outcome after ARDS should consider the impact of ventilatory variables., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JG received consultant fees and speaker's honoraria from Drägerwerk AG & Co. KGaA and GE HealthCare Technologies, Inc. SK received research support from Cytosorbents and Daiichi Sankyo, lecture honoraria from ADVITOS, Biotest, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Shionogi and Zoll, consultant fees from Fresenius, Gilead, MSD and Pfizer. Maria Schroeder received research support and speaker's honoraria from Pfizer Pharma GmbH.- Published
- 2024
- Full Text
- View/download PDF
16. Dual-Energy CT muscle fat fraction as a new imaging biomarker of body composition and survival predictor in critically ill patients.
- Author
-
Erley J, Roedl K, Ozga AK, de Heer G, Schubert N, Breckow J, Burdelski C, Tahir E, Kluge S, Huber TB, Yamamura J, Adam G, and Molwitz I
- Abstract
Objective: To analyze changes in the muscular fat fraction (FF) during immobilization at the intensive care unit (ICU) using dual-energy CT (DECT) and evaluate the predictive value of the DECT FF as a new imaging biomarker for morbidity and survival., Methods: Immobilized ICU patients (n = 81, 43.2% female, 60.3 ± 12.7 years) were included, who received two dual-source DECT scans (CT1, CT2) within a minimum interval of 10 days between 11/2019 and 09/2022. The DECT FF was quantified for the posterior paraspinal muscle by two radiologists using material decomposition. The skeletal muscle index (SMI), muscle radiodensity attenuation (MRA), subcutaneous-/ visceral adipose tissue area (SAT, VAT), and waist circumference (WC) were assessed. Reasons for ICU admission, clinical scoring systems, therapeutic regimes, and in-hospital mortality were noted. Linear mixed models, Cox regression, and intraclass correlation coefficients were employed., Results: Between CT1 and CT2 (median 21 days), the DECT FF increased (from 20.9% ± 12.0 to 27.0% ± 12.0, p = 0.001). The SMI decreased (35.7 cm
2 /m2 ± 8.8 to 31.1 cm2 /m2 ± 7.6, p < 0.001) as did the MRA (29 HU ± 10 to 26 HU ± 11, p = 0.009). WC, SAT, and VAT did not change. In-hospital mortality was 61.5%. In multivariable analyses, only the change in DECT FF was associated with in-hospital mortality (hazard ratio (HR) 9.20 [1.78-47.71], p = 0.008), renal replacement therapy (HR 48.67 [9.18-258.09], p < 0.001), and tracheotomy at ICU (HR 37.22 [5.66-245.02], p < 0.001). Inter-observer reproducibility of DECT FF measurements was excellent (CT1: 0.98 [0.97; 0.99], CT2: 0.99 [0.96-0.99])., Conclusion: The DECT FF appears to be suitable for detecting increasing myosteatosis. It seems to have predictive value as a new imaging biomarker for ICU patients., Clinical Relevance Statement: The dual-energy CT muscular fat fraction appears to be a robust imaging biomarker to detect and monitor myosteatosis. It has potential for prognosticating, risk stratifying, and thereby guiding therapeutic nutritional regimes and physiotherapy in critically ill patients., Key Points: The dual-energy CT muscular fat fraction detects increasing myosteatosis caused by immobilization. Change in dual-energy CT muscular fat fraction was a predictor of in-hospital morbidity and mortality. Dual-energy CT muscular fat fraction had a predictive value superior to established CT body composition parameters., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
17. Characteristics and Outcome Analysis for Intensive Care Patients Undergoing Decompressive Laparotomy for Abdominal Compartment Syndrome: Impact of Extracorporeal Membrane Oxygenation Support.
- Author
-
Nitschke C, Schulte M, Izbicki JR, Hackert T, Kluge S, Burdelski C, and Bachmann K
- Abstract
(1) Background: Abdominal compartment syndrome (ACS) is a life-threatening situation and is associated with high mortality in the intensive care unit (ICU). Decompressive laparotomy represents the last therapeutic option. This cohort study aims to optimize the selection of ICU patients suffering from ACS who benefit from decompressive laparotomy. (2) Methods: All available data from adult patients treated at the 12 ICUs of a university hospital between 2011 and 2019 were included. Outcome parameters for patients with and without extracorporeal membrane oxygenation (ECMO) were compared. (3) Results: 207 ICU patients with ACS undergoing surgery were identified. Laparotomy resulted in immediate improvement of organ functions in 15% of patients, who then survived more frequently. The overall mortality rate in our cohort was 69%. The group of ECMO patients-including va- and vv-ECMO-showed significantly less organ function improvement and a higher mortality rate of 79% compared to a better postoperative improvement and a lower mortality rate of 62% in non-ECMO patients. (4) Conclusions: There are ICU patients who benefit from decompressive laparotomy-nevertheless, mortality is high. Non-ECMO patients have a better prognosis than ECMO patients. Our findings can support clinical decision-making on emergency surgery and the development of future guidelines.
- Published
- 2023
- Full Text
- View/download PDF
18. Effect of Hemadsorption Therapy in Critically Ill Patients with COVID-19 (CYTOCOV-19): A Prospective Randomized Controlled Pilot Trial.
- Author
-
Jarczak D, Roedl K, Fischer M, de Heer G, Burdelski C, Frings DP, Sensen B, Boenisch O, Tariparast PA, Kluge S, and Nierhaus A
- Subjects
- Humans, Interleukin-6, Hemadsorption, Critical Illness, Prospective Studies, Pilot Projects, Norepinephrine, COVID-19
- Abstract
Introduction: Immunomodulatory therapies have shown beneficial effects in patients with severe COVID-19. Patients with hypercytokinemia might benefit from the removal of inflammatory mediators via hemadsorption., Methods: Single-center prospective randomized trial at the University Medical Center Hamburg-Eppendorf (Germany). Patients with confirmed COVID-19, refractory shock (norepinephrine ≥0.2 µg/kg/min to maintain a mean arterial pressure ≥65 mm Hg), interleukin-6 (IL-6) ≥500 ng/L, and an indication for renal replacement therapy or extracorporeal membrane oxygenation were included. Patients received either hemadsorption therapy (HT) or standard medical therapy (SMT). For HT, a CytoSorb® adsorber was used for up to 5 days and was replaced every 18-24 h. The primary endpoint was sustained hemodynamic improvement (norepinephrine ≤0.05 µg/kg/min ≥24 h)., Results: Of 242 screened patients, 24 were randomized and assigned to either HT (N = 12) or SMT (N = 12). Both groups had similar severity as assessed by SAPS II (median 75 points HT group vs. 79 SMT group, p = 0.590) and SOFA (17 vs. 16, p = 0.551). Median IL-6 levels were 2,269 (IQR 948-3,679) and 3,747 (1,301-5,415) ng/L in the HT and SMT groups at baseline, respectively (p = 0.378). Shock resolution (primary endpoint) was reached in 33% (4/12) versus 17% (2/12) in the HT and SMT groups, respectively (p = 0.640). Twenty-eight-day mortality was 58% (7/12) in the HT compared to 67% (8/12) in the SMT group (p = 1.0). During the treatment period of 5 days, 6/12 (50%) of the SMT patients died, in contrast to 1/12 (8%) in the HT group., Conclusion: HT was associated with a non-significant trend toward clinical improvement within the intervention period. In selected patients, HT might be an option for stabilization before transfer and further therapeutic decisions. This finding warrants further investigation in larger trials., (© 2022 S. Karger AG, Basel.)
- Published
- 2023
- Full Text
- View/download PDF
19. Outcomes of critically ill coronavirus disease 2019 patients requiring kidney replacement therapy: A retrospective cohort study.
- Author
-
Braunsteiner J, Jarczak D, Schmidt-Lauber C, Boenisch O, de Heer G, Burdelski C, Frings D, Sensen B, Nierhaus A, Hoxha E, Huber TB, Wichmann D, Kluge S, Fischer M, and Roedl K
- Abstract
Background: Coronavirus disease 2019 (COVID-19) has resulted in high hospitalization rates worldwide. Acute kidney injury (AKI) in patients hospitalized for COVID-19 is frequent and associated with disease severity and poor outcome. The aim of this study was to investigate the incidence of kidney replacement therapy (KRT) in critically ill patients with COVID-19 and its implication on outcome., Methods: We retrospectively analyzed all COVID-19 patients admitted to the Department of Intensive Care Medicine at the University Medical Center Hamburg-Eppendorf (Germany) between 1 March 2020 and 31 July 2021. Demographics, clinical parameters, type of organ support, length of intensive care unit (ICU) stay, mortality and severity scores were assessed., Results: Three-hundred critically ill patients with COVID-19 were included. The median age of the study population was 61 (IQR 51-71) years and 66% ( n = 198) were male. 73% ( n = 219) of patients required invasive mechanical ventilation. Overall, 68% ( n = 204) of patients suffered from acute respiratory distress syndrome and 30% ( n = 91) required extracorporeal membrane oxygenation (ECMO). We found that 46% ( n = 139) of patients required KRT. Septic shock (OR 11.818, 95% CI: 5.941-23.506, p < 0.001), higher simplified acute physiology scores (SAPS II) (OR 1.048, 95% CI: 1.014-1.084, p = 0.006) and vasopressor therapy (OR 5.475, 95% CI: 1.127-26.589, p = 0.035) were independently associated with the initiation of KRT. 61% ( n = 85) of patients with and 18% ( n = 29) without KRT died in the ICU ( p < 0.001). Cox regression found that KRT was independently associated with mortality (HR 2.075, 95% CI: 1.342-3.208, p = 0.001) after adjusting for confounders., Conclusion: Critically ill patients with COVID-19 are at high risk of acute kidney injury with about half of patients requiring KRT. The initiation of KRT was associated with high mortality., Competing Interests: Author SK received research support by Ambu, E.T.View Ltd., Fisher & Paykel, Pfizer, and Xenios, lecture honorarium from ArjoHuntleigh, Astellas, Astra, Basilea, Bard, Baxter, Biotest, CSL Behring, Cytosorbents, Fresenius, Gilead, MSD, Orion, Pfizer, Philips, Sedana, Sorin, Xenios, and Zoll, and consultant honorarium from AMOMED, Astellas, Baxter, Bayer, Fresenius, Gilead, MSD, Pfizer, and Xenios. Author DW received lecture honorarium from 3M, ADVANZ (previously Correvio), AMEOS, Gilead, Kite, Lilly, MSD, Pfizer, and Shionogi and consultation honorarium from Eumedica, EUSA-Pharm, Gilead, Kite, MSD, Novartis, Pfizer, and Shionogi. No other potential conflict of interest relevant to this article was reported. Author AN received research funds, lecture honoraria and travel reimbursement within the last 5 years from CytoSorbents Europe, Biotest AG, and Thermo Fisher Scientific. Author DF reports lecture honoraria within the last 5 years from Xenios AG. Author KR received travel reimbursement from Gilead within the last 5 years. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Braunsteiner, Jarczak, Schmidt-Lauber, Boenisch, de Heer, Burdelski, Frings, Sensen, Nierhaus, Hoxha, Huber, Wichmann, Kluge, Fischer and Roedl.)
- Published
- 2022
- Full Text
- View/download PDF
20. Importance of computed tomography muscle quality and continuous versus cut-off-based sarcopenia detection in major hepatic surgery.
- Author
-
Molwitz I, Kemper M, Krause L, Adam G, Izbicki JR, Burdelski C, de Heer G, Gerdes L, Yamamura J, and Li J
- Abstract
Background: The role of the computed tomography (CT)-derived skeletal muscle index (SMI) as a parameter of muscle quantity on the outcome after major liver resection remains contradictory and that of the muscle radiodensity attenuation (MRA) as a parameter of muscle quality has not been sufficiently evaluated. This observational study aimed to investigate the influence of metric SMI and MRA values and cut-off-based CT sarcopenia detection on liver-surgery specific complications measured by the new FABIB (liver failure, ascites, biliary leakage, infection, bleeding) score and survival after hemihepatectomy., Methods: A total of 183 patients with major hepatectomy were retrospectively included. The SMI and MRA were determined from the abdominal muscle area of preoperative CT scans. Patients were classified as sarcopenic by the SMI and MRA cut-off values of Prado et al. , Martin et al. , and van der Werf et al. Postoperative complications were documented according to the Clavien-Dindo classification and FABIB score. The relation of the continuous, non-categoric SMI and MRA values and of the cut-off-based sarcopenia detection to the postoperative complications and survival was analyzed by multivariable linear, logistic, and Cox proportional hazards regression., Results: A higher MRA was associated with less severe postoperative complications in the Clavien-Dindo [-0.59 (95% CI: -0.95 to -0.23), P=0.002] and the FABIB score [-0.65 (95% CI: -1.19 to -0.12), P=0.017]. An increase of the SMI did not result in less severe complications in the Clavien-Dindo [0.14 (95% CI: -0.27 to 0.55), P=0.503] or FABIB score [0.17 (95% CI: -0.42 to 0.76), P=0.572]. For patients classified as sarcopenic by the cut-off-based systems no relevant relation to postoperative complications was found. Overall survival was better for a higher MRA [hazard ratio (HR): 0.75 (95% CI: 0.58-0.97), P=0.029], as long-term survival was for a higher SMI [HR: 0.68 (95% CI: 0.47-0.96), P=0.031]. Only below van der Werf's MRA cut-off the probability of overall and long-term survival was reduced [HR: 2.32 (95% CI: 1.18-4.54), P=0.015; 2.68 (95% CI: 1.25-5.74), P=0.011]., Conclusions: The MRA has a stronger influence on complications in the Clavien-Dindo classification and the liver-surgery specific FABIB score than the SMI. Continuous, non-categoric MRA and SMI values are superior to cut-off-based systems in predicting the outcome after major hepatic surgery., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-21-5948/coif). MK was supported with a partial exemption from his clinical duties by the Clinician Scientist Program of the University Medical Center Hamburg-Eppendorf. The other authors have no conflicts of interest to declare., (2022 Annals of Translational Medicine. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
21. Blunt traumatic right coronary artery dissection presenting with second-degree atrioventricular block and late-onset severe cardiogenic shock.
- Author
-
Paparoupa M, Conradi L, Warncke ML, Well L, Burdelski C, Cramer C, Grahn H, Kubik M, and Kluge S
- Subjects
- Adolescent, Coronary Vessels diagnostic imaging, Coronary Vessels injuries, Coronary Vessels surgery, Humans, Shock, Cardiogenic diagnosis, Shock, Cardiogenic etiology, Shock, Cardiogenic therapy, Aortic Dissection complications, Aortic Dissection diagnostic imaging, Atrioventricular Block diagnosis, Atrioventricular Block etiology, Atrioventricular Block therapy, Thoracic Injuries complications, Thoracic Injuries diagnostic imaging, Thoracic Injuries surgery, Wounds, Nonpenetrating complications, Wounds, Nonpenetrating diagnostic imaging
- Abstract
Background: Blunt chest injury may induce several cardiovascular traumata, requiring immediate care. Right coronary artery dissection (RCA) is an extremely rare sequela in this setting and is associated with high mortality, if it remains undiagnosed. Case presentation We present the case of an RCA dissection after blunt chest trauma in a 16-year-old patient, who initially presented with a second-degree atrioventricular block as solitary manifestation on admission. Typical electrocardiographic findings, such as ST segmental changes or pathological Q waves were absent. Serial echocardiograms excluded segmental motion abnormalities, pericardial effusion or right ventricular strain. Nevertheless, a complementary computed tomography coronary angiography revealed this potentially lethal condition several hours later. The patient underwent an emergency surgical myocardial revascularization under the circulatory support of veno-arterial extracorporeal membrane oxygenation and suffered a prolonged right ventricular insufficiency with severe late-onset cardiogenic shock, due to an extensive myocardial infarction of the inferoseptal ventricular wall., Conclusion: Right coronary artery dissection after high-speed blunt chest injury constitutes a diagnostic challenge, especially in the absence of typical electrocardiographic and echocardiographic findings in young patients. This condition may dramatically deteriorate in time, leading to severe cardiogenic shock and life-threatening arrhythmias., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
22. Surgical correction of a percutaneous dilatational tracheostomy: A case report.
- Author
-
Aldemyati R, Paparoupa M, Kluge S, Grotelüschen R, and Burdelski C
- Abstract
Introduction and Importance: Percutaneous dilatational tracheostomy (PDT) has become a routine procedure in intensive care, because of its multiple advantages over surgical tracheostomy (ST)., Case Presentation: We present the case of a 72-year-old patient with SARS-CoV-2 pneumonia, who received a PDT in the 6th tracheal ring with a lateral puncture of the trachea. This atypical placement of tracheostomy was due to a massive left-pronounced goiter, causing a tracheal shift to the right. To avoid dislocation of the tracheal cannula and prevent recurrent bleeding, surgical revision was decided. After left hemithyroidectomy, oral intubation was temporarily necessary, in order to remove the old tracheostomy. Then suturing of the left lateral tracheal defect and standard ST in the 2nd tracheal cartilage was performed. The patient was successfully weaned and decannulated and his swallowing function remained intact., Clinical Discussion: In our case left hemithyroidectomy was necessary, in order to enable an optimal surgical tracheostomy in the 2nd tracheal cartilage. Because mechanical ventilation was carried out proximal to the large tracheal defect after PCT, a secondary closing approach was not an option. The endotracheal cuff was placed above the defect, in order to prevent acute or chronic intraluminal pressure trauma. Postoperative x-ray and bronchoscopy insured the sufficient sealing of the tracheal suturing., Conclusion: We describe an unusual placement of percutaneous dilatational tracheostomy through a thyroid goiter and our approach to perform a correction surgical tracheostomy., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
23. Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial.
- Author
-
Karakas M, Akin I, Burdelski C, Clemmensen P, Grahn H, Jarczak D, Keßler M, Kirchhof P, Landmesser U, Lezius S, Lindner D, Mebazaa A, Nierhaus A, Ocak A, Rottbauer W, Sinning C, Skurk C, Söffker G, Westermann D, Zapf A, Zengin E, Zeller T, and Kluge S
- Subjects
- Adolescent, Adult, Aged, Double-Blind Method, Female, Humans, Lung, Male, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Shock, Cardiogenic drug therapy
- Abstract
Background: Cardiogenic shock has a high mortality on optimal therapy. Adrenomedullin is released during cardiogenic shock and is involved in its pathophysiological processes. This study assessed treatment with the humanised, monoclonal, non-neutralising, adrenomedullin antibody adrecizumab, increasing circulating concentrations of adrenomedullin in cardiogenic shock., Methods: In this investigator-initiated, placebo-controlled, double-blind, multicentre, randomised trial (ACCOST-HH), patients were recruited from four university hospitals in Germany. Patients were eligible if they were 18 years old or older and hospitalised for cardiogenic shock within the last 48 h. Exclusion criteria were resuscitation for longer than 60 min and cardiogenic shock due to sustained ventricular tachycardia or bradycardia. Adult patients in cardiogenic shock were randomly assigned (1:1) to intravenous adrecizumab (8 mg/kg bodyweight) or placebo using an internet-based software. A block randomisation procedure was applied with stratification by age (older vs younger than 65 years), sex (male vs female), and type of underlying cardiogenic shock (acute myocardial infarction vs other entities). Investigators, patients, and medical staff involved in patient care were masked to group assignment. The primary endpoint was number of days up to day 30 without the need for cardiovascular organ support, defined as vasopressor therapy, inotropes, or mechanical circulatory support (or both) assessed in the intention-to-treat population. Safety outcomes included therapy-emergent serious adverse events, severe adverse events, adverse events, suspected unexpected serious adverse reactions, study drug-related mortality, and total mortality. The trial was registered at ClinicalTrials.gov, NCT03989531, and EudraCT, 2018-002824-17, and is now complete., Findings: Between April 5, 2019, and Jan 13, 2021, 150 patients were enrolled: 77 (51%) were randomly assigned to adrecizumab and 73 (49%) to placebo. All patients received the allocated treatment. The number of days without the need for cardiovascular organ support was not different between patients receiving adrecizumab or placebo (12·37 days [95% CI 9·80-14·94] vs 14·05 [11·41-16·69]; adjusted mean difference -1·69 days [-5·37 to 2·00]; p=0·37). Serious adverse events occurred in 59 patients receiving adrecizumab and in 57 receiving placebo (odds ratio 0·92 [95% CI 0·43-1·98]; p=0·83). Mortality was not different between groups at 30 days (hazard ratio 0·99 [95% CI 0·60-1·65]; p=0·98) or 90 days (1·10 [0·68-1·77]; p=0·71)., Interpretation: Adrecizumab was well tolerated in patients with cardiogenic shock but did not reduce the need for cardiovascular organ support or improve survival at days 30 and 90., Funding: Adrenomed AG and University Hospital of Hamburg., Competing Interests: Declaration of interests SK reports grants and non-financial support from Ambu, Daiichi Sankyo, ETView Ltd, Fisher & Paykel, Pfizer, and Xenios; personal fees from Astra, C R Bard, Baxter, Biotest, Cytosorbents, Daiichi Sankyo, Fresenius, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Philips, Zoll, Bayer, Fresenius, Gilead, MSD and Pfizer, outside of the submitted work. TZ reports grants from Vifor Pharma, outside of the submitted work. PC reports personal fees from Abbott, Acarix, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Evolva, Fibrex, Janssen, Merck, Myogen, Medtronic, Mitsubishi Pharma, The Medicines Company, Nycomed, Organon, Pfizer, Pharmacia, Regado, Sanofi, Searle, and Servier, outside of the submitted work. PK reports research support for basic, translational, and clinical research projects from the EU, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, and from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but has not received honoraria in the past 3 years. PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). UL reports grant support from Bayer and Novartis, and personal fees from AstraZeneca, Amgen, Bayer, Sanofi, Berlin Chemie, Novartis, Abbott, and the Medicines Company, outside of the submitted work. AM reports grant support from Adrenomed, 4TEEN4, Abbott, Roche, and Sphingotec, and personal fees from Orion, Novartis, Roche, and Servier, outside of the submitted work. CSk reports grant support from Bayer, and personal fees from Abiomed, Boston-Scientific, and Bristol Myers Squibb, outside of the submitted work. DW reports personal fees from AstraZeneca, Bayer, Berlin-Chemie, and Novartis, outside of the submitted work. MKa reports grant and non-financial support from Adrenomed AG and Vifor, and personal fees from Adrenomed AG, Sphingotec, Vifor, and 4TEEN4, outside of the submitted work. All other authors declare no competing interests., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
24. Necrotizing Soft Tissue Infections in Intensive Care.
- Author
-
Ogica A, Burdelski C, Rohde H, Kluge S, and de Heer G
- Subjects
- Critical Care, Female, Humans, Intensive Care Units, Male, Prognosis, Retrospective Studies, Sepsis, Shock, Septic therapy, Soft Tissue Infections diagnosis, Soft Tissue Infections therapy
- Abstract
Background: Necrotizing soft tissue infections (NSTIs) are typically characterized by extensive soft tissue destruction with systemic signs of toxicity, ranging from sepsis to septic shock. Our aim was to analyze the clinical characteristics, microbiological results, laboratory data, therapies, and outcome of patients with NSTIs admitted to an intensive care unit (ICU)., Methods: A monocentric observational study of patients admitted to the ICU of a university hospital between January 2009 and December 2017. The demographic characteristics, comorbidities, clinical features, microbiology and laboratory results, organ dysfunctions, therapies, and outcome were retrospectively analyzed., Results: There were 59 patients and 70% males. The mean age (± SD) was 55 ± 18; type II (monomicrobial) NSTI was present in 36 patients (61%); the most common isolated pathogen was Streptococcus pyogenes in 28 patients (48%). Septic shock was diagnosed in 41 patients (70%). The most common organ dysfunctions were circulatory and renal in 42 (71%) and 38 patients (64%). The mean value (± SD) of serum lactate at admission to the ICU was 4.22 ± 5.42 mmol/l, the median SOFA score and SAPS II were 7 (IQR 4 - 10) and 46 (IQR 30.5 - 53). ICU mortality rate was 25%. Both SOFA score and serum lactate demonstrated a good prognostic value regarding ICU outcome (OR 1.29, 95%CI 1.07-1.57, P < 0.007 and OR 1.53, 95%CI 1.19-1.98, P < 0.001). A cut-off value for serum lactate of 6.55 mmol/L positively predicted mortality with 67% sensitivity and 97% specificity., Conclusion: NSTIs carry a high risk of septic shock and multiple organ dysfunction syndrome and thus are still associated with high mortality. In our study, the value of serum lactate at admission to the ICU correlated well with mortality. This easy-to-measure parameter could play a role in the decision-making process regarding prognosis and continuation of care.
- Published
- 2022
- Full Text
- View/download PDF
25. Chronic Critical Illness in Patients with COVID-19: Characteristics and Outcome of Prolonged Intensive Care Therapy.
- Author
-
Roedl K, Jarczak D, Boenisch O, de Heer G, Burdelski C, Frings D, Sensen B, Nierhaus A, Kluge S, and Wichmann D
- Abstract
The spread of SARS-CoV-2 caused a worldwide healthcare threat. High critical care admission rates related to Coronavirus Disease 2019 (COVID-19) respiratory failure were observed. Medical advances helped increase the number of patients surviving the acute critical illness. However, some patients require prolonged critical care. Data on the outcome of patients with a chronic critical illness (CCI) are scarce. Single-center retrospective study including all adult critically ill patients with confirmed COVID-19 treated at the Department of Intensive Care Medicine at the University Medical Center Hamburg-Eppendorf, Germany, between 1 March 2020 and 8 August 2021. We identified 304 critically ill patients with COVID-19 during the study period. Of those, 55% ( n = 167) had an ICU stay ≥21 days and were defined as chronic critical illness, and 45% ( n = 137) had an ICU stay <21 days. Age, sex and BMI were distributed equally between both groups. Patients with CCI had a higher median SAPS II (CCI: 39.5 vs. no-CCI: 38 points, p = 0.140) and SOFA score (10 vs. 6, p < 0.001) on admission. Seventy-three per cent ( n = 223) of patients required invasive mechanical ventilation (MV) (86% vs. 58%; p < 0.001). The median duration of MV was 30 (17-49) days and 7 (4-12) days in patients with and without CCI, respectively ( p < 0.001). The regression analysis identified ARDS (OR 3.238, 95% CI 1.827-5.740, p < 0.001) and referral from another ICU (OR 2.097, 95% CI 1.203-3.654, p = 0.009) as factors significantly associated with new-onset of CCI. Overall, we observed an ICU mortality of 38% ( n = 115) in the study cohort. In patients with CCI we observed an ICU mortality of 28% ( n = 46) compared to 50% ( n = 69) in patients without CCI ( p < 0.001). The 90-day mortality was 28% ( n = 46) compared to 50% ( n = 70), respectively ( p < 0.001). More than half of critically ill patients with COVID-19 suffer from CCI. Short and long-term survival rates in patients with CCI were high compared to patients without CCI, and prolonged therapy should not be withheld when resources permit prolonged therapy.
- Published
- 2022
- Full Text
- View/download PDF
26. Clinical Characteristics, Complications and Outcomes of Patients with Severe Acute Respiratory Distress Syndrome Related to COVID-19 or Influenza Requiring Extracorporeal Membrane Oxygenation-A Retrospective Cohort Study.
- Author
-
Roedl K, Kahn A, Jarczak D, Fischer M, Boenisch O, de Heer G, Burdelski C, Frings D, Sensen B, Nierhaus A, Braune S, Yildirim Y, Bernhardt A, Reichenspurner H, Kluge S, and Wichmann D
- Abstract
Extracorporeal membrane oxygenation (ECMO) represents a viable therapy option for patients with refractory acute respiratory distress syndrome (ARDS). Currently, veno-venous (vv) ECMO is frequently used in patients suffering from coronavirus disease 2019 (COVID-19). VV-ECMO was also frequently utilised during the influenza pandemic and experience with this complex and invasive treatment has increased worldwide since. However, data on comparison of clinical characteristics and outcome of patients with COVID-19 and influenza-related severe ARDS treated with vv-ECMO are scarce. This is a retrospective analysis of all consecutive patients treated with vv/(veno-arterial)va-ECMO between January 2009 and January 2021 at the University Medical Centre Hamburg-Eppendorf in Germany. All patients with confirmed COVID-19 or influenza were included. Patient characteristics, parameters related to ICU and vv/va-ECMO as well as clinical outcomes were compared. Mortality was assessed up to 90 days after vv/va-ECMO initiation. Overall, 113 patients were included, 52 (46%) with COVID-19 and 61 (54%) with influenza-related ARDS. Median age of patients with COVID-19 and influenza was 58 (IQR 53-64) and 52 (39-58) years ( p < 0.001), 35% and 31% ( p = 0.695) were female, respectively. Charlson Comorbidity Index was 3 (1-5) and 2 (0-5) points in the two groups ( p = 0.309). Median SAPS II score pre-ECMO was 27 (24-36) vs. 32 (28-41) points ( p = 0.009), and SOFA score was 13 (11-14) vs. 12 (8-15) points ( p = 0.853), respectively. Median P/F ratio pre-ECMO was 64 (46-78) and 73 (56-104) ( p = 0.089); pH was 7.20 (7.16-7.29) and 7.26 (7.18-7.33) ( p = 0.166). Median days on vv/va-ECMO were 17 (7-27) and 11 (7-20) ( p = 0.295), respectively. Seventy-one percent and sixty-nine percent had renal replacement therapy ( p = 0.790). Ninety-four percent of patients with COVID-19 and seventy-seven percent with influenza experienced vv/va-ECMO-associated bleeding events ( p = 0.004). Thirty-four percent and fifty-five percent were successfully weaned from ECMO ( p = 0.025). Ninety-day mortality was 65% and 57% in patients with COVID-19 and influenza, respectively ( p = 0.156). Median length of ICU stay was 24 (13-44) and 28 (16-14) days ( p = 0.470), respectively. Despite similar disease severity, the use of vv/va-ECMO in ARDS related to COVID-19 and influenza resulted in similar outcomes at 90 days. A significant higher rate of bleeding complications and thrombosis was observed in patients with COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
27. Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19.
- Author
-
Woo MS, Haag F, Nierhaus A, Jarczak D, Roedl K, Mayer C, Brehm TT, van der Meirschen M, Hennigs A, Christopeit M, Fiedler W, Karagiannis P, Burdelski C, Schultze A, Huber S, Addo MM, Schmiedel S, Friese MA, Kluge S, and Schulze Zur Wiesch J
- Abstract
COVID-19 is a respiratory tract infection that can affect multiple organ systems. Predicting the severity and clinical outcome of individual patients is a major unmet clinical need that remains challenging due to intra- and inter-patient variability. Here, we longitudinally profiled and integrated more than 150 clinical, laboratory, and immunological parameters of 173 patients with mild to fatal COVID-19. Using systems biology, we detected progressive dysregulation of multiple parameters indicative of organ damage that correlated with disease severity, particularly affecting kidneys, hepatobiliary system, and immune landscape. By performing unsupervised clustering and trajectory analysis, we identified T and B cell depletion as early indicators of a complicated disease course. In addition, markers of hepatobiliary damage emerged as robust predictor of lethal outcome in critically ill patients. This allowed us to propose a novel clinical CO VID-19 S everi T y (COST) score that distinguishes complicated disease trajectories and predicts lethal outcome in critically ill patients., Competing Interests: The authors declare no competing interests., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
28. MR-proAdrenomedullin as a predictor of renal replacement therapy in a cohort of critically ill patients with COVID-19.
- Author
-
Roedl K, Jarczak D, Fischer M, Haddad M, Boenisch O, de Heer G, Burdelski C, Frings D, Sensen B, Karakas M, Kluge S, and Nierhaus A
- Subjects
- Acute Kidney Injury diagnosis, Aged, Biomarkers metabolism, COVID-19 virology, Cohort Studies, Female, Germany, Hospitals, University, Humans, Intensive Care Units, Male, Middle Aged, Predictive Value of Tests, ROC Curve, SARS-CoV-2 physiology, Acute Kidney Injury therapy, Adrenomedullin metabolism, COVID-19 prevention & control, Critical Illness therapy, Protein Precursors metabolism, Renal Replacement Therapy methods, SARS-CoV-2 isolation & purification
- Abstract
Background: About 20% of ICU patients with COVID-19 require renal replacement therapy (RRT). Mid-regional pro-adrenomedullin (MR-proADM) might be used for risk assessment. This study investigates MR-proADM for RRT prediction in ICU patients with COVID-19., Methods: We analysed data of consecutive patients with COVID-19, requiring ICU admission at a university hospital in Germany between March and September 2020. Clinical characteristics, details on AKI, and RRT were assessed. MR-proADM was measured on admission., Results: 64 patients were included (49 (77%) males). Median age was 62.5y (54-73). 47 (73%) patients were ventilated and 50 (78%) needed vasopressors. 25 (39%) patients had severe ARDS, and 10 patients needed veno-venous extracorporeal membrane oxygenation. 29 (45%) patients required RRT; median time from admission to RRT start was 2 (1-9) days. MR-proADM on admission was higher in the RRT group (2.491 vs. 1.23 nmol/l; p = 0.002) and showed the highest correlation with renalSOFA. ROC curve analysis showed that MR-proADM predicts RRT with an AUC of 0.69 (95% CI: 0.543-0.828; p = 0.019). In multivariable logistic regression MR-proADM was an independent predictor (OR: 3.813, 95% CI 1.110-13.102, p <0.05) for RRT requirement., Conclusion: AKI requiring RRT is frequent in ICU patients with COVID-19. MR-proADM on admission was able to predict RRT requirement, which may be of interest for risk stratification and management.
- Published
- 2021
- Full Text
- View/download PDF
29. Are muscle parameters obtained by computed tomography associated with outcome after esophagectomy for cancer?
- Author
-
Kemper M, Molwitz I, Krause L, Reeh M, Burdelski C, Kluge S, Yamamura J, Izbicki JR, and de Heer G
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Length of Stay, Male, Middle Aged, Morbidity, Mortality, Postoperative Complications, Survival Analysis, Tomography, X-Ray Computed, Carcinoma surgery, Esophageal Neoplasms surgery, Esophagectomy, Muscle, Skeletal pathology, Risk Assessment methods, Sarcopenia pathology
- Abstract
Background & Aims: Esophageal cancer patients often suffer from cancer-related malnutrition and, as a result, sarcopenia. Whether sarcopenia worsens the outcome after esophagectomy is unclear. Inconsistent study results are partly caused by varying cut-off values used for defining sarcopenia. To overcome this challenge, a new statistical approach is proposed in this study: analyzing the linear association of computer tomography derived muscle parameters with important clinical short- and long-term outcomes post esophagectomy, regardless of cut-offs., Methods: Skeletal muscle index (SMI), quantifying muscle mass, was assessed with computed tomography (CT) in 98 patients undergoing esophagectomy. Muscle radiation attenuation (MRA) was measured to evaluate muscle quality. To evaluate the influence of the SMI and MRA on post-surgery complications, logistic regression models were used. To analyze the relationship of lengths of stay to muscle parameters, the competing risk approach introduced by Fine and Gray was applied. For survival analysis, log-rank test and Cox proportional hazards regression modeling were used., Results: Neither a relevant association of SMI nor MRA with pneumonia and esophagoenteric leak were observed. Furthermore, no relevant association to lengths of stay in intensive care or hospital were detected. If the SMI increased, the odds for pleural effusion and pleural empyema decreased, but the odds of a pulmonary embolism increased. Univariate, unadjusted long-term survival analysis revealed that lower MRA and lower SMI were associated with shorter survival (P = 0.03). However, if the analysis was adjusted for confounders, e.g., Charlson Comorbidity Index, no relevant association regarding long-term survival was detected., Conclusion: Consequently, poor muscle status, determined by CT imaging, does not justify denying a patient an oncologic resection. The Charlson Comorbidity Index, however, was superior for preoperative risk stratification., Competing Interests: Conflicts of interest The authors declare no competing interests., (Copyright © 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
30. Characteristics and Risk Factors for Intensive Care Unit Cardiac Arrest in Critically Ill Patients with COVID-19-A Retrospective Study.
- Author
-
Roedl K, Söffker G, Wichmann D, Boenisch O, de Heer G, Burdelski C, Frings D, Sensen B, Nierhaus A, Westermann D, Kluge S, and Jarczak D
- Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the coronavirus disease 2019 (COVID-19) led to an ongoing pandemic with a surge of critically ill patients. Very little is known about the occurrence and characteristic of cardiac arrest in critically ill patients with COVID-19 treated at the intensive care unit (ICU). The aim was to investigate the incidence and outcome of intensive care unit cardiac arrest (ICU-CA) in critically ill patients with COVID-19. This was a retrospective analysis of prospectively recorded data of all consecutive adult patients with COVID-19 admitted (27 February 2020-14 January 2021) at the University Medical Centre Hamburg-Eppendorf (Germany). Of 183 critically ill patients with COVID-19, 18% ( n = 33) had ICU-CA. The median age of the study population was 63 (55-73) years and 66% ( n = 120) were male. Demographic characteristics and comorbidities did not differ significantly between patients with and without ICU-CA. Simplified Acute Physiological Score II (SAPS II) (ICU-CA: median 44 points vs. no ICU-CA: 39 points) and Sequential Organ Failure Assessment (SOFA) score (median 12 points vs. 7 points) on admission were significantly higher in patients with ICU-CA. Acute respiratory distress syndrome (ARDS) was present in 91% ( n = 30) with and in 63% ( n = 94) without ICU-CA ( p = 0.002). Mechanical ventilation was more common in patients with ICU-CA (97% vs. 67%). The median stay in ICU before CA was 6 (1-17) days. A total of 33% ( n = 11) of ICU-CAs occurred during the first 24 h of ICU stay. The initial rhythm was non-shockable (pulseless electrical activity (PEA)/asystole) in 91% ( n = 30); 94% ( n = 31) had sustained return of spontaneous circulation (ROSC). The median time to ROSC was 3 (1-5) minutes. Patients with ICU-CA had significantly higher ICU mortality (61% vs. 37%). Multivariable logistic regression showed that the presence of ARDS (odds ratio (OR) 4.268, 95% confidence interval (CI) 1.211-15.036; p = 0.024) and high SAPS II (OR 1.031, 95% CI 0.997-1.065; p = 0.077) were independently associated with the occurrence of ICU-CA. A total of 18% of critically ill patients with COVID-19 suffered from a cardiac arrest within the intensive care unit. The occurrence of ICU-CA was associated with presence of ARDS and severity of illness.
- Published
- 2021
- Full Text
- View/download PDF
31. Severe liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect?
- Author
-
Roedl K, Jarczak D, Drolz A, Wichmann D, Boenisch O, de Heer G, Burdelski C, Frings D, Sensen B, Nierhaus A, Lütgehetmann M, Kluge S, and Fuhrmann V
- Abstract
Background: SARS-CoV-2 caused a pandemic and global threat for human health. Presence of liver injury was commonly reported in patients with coronavirus disease 2019 (COVID-19). However, reports on severe liver dysfunction (SLD) in critically ill with COVID-19 are lacking. We evaluated the occurrence, clinical characteristics and outcome of SLD in critically ill patients with COVID-19., Methods: Clinical course and laboratory was analyzed from all patients with confirmed COVID-19 admitted to ICU of the university hospital. SLD was defined as: bilirubin ≥ 2 mg/dl or elevation of aminotransferase levels (> 20-fold ULN)., Results: 72 critically ill patients were identified, 22 (31%) patients developed SLD. Presenting characteristics including age, gender, comorbidities as well as clinical presentation regarding COVID-19 overlapped substantially in both groups. Patients with SLD had more severe respiratory failure (paO
2 /FiO2: 82 (58-114) vs. 117 (83-155); p < 0.05). Thus, required more frequently mechanical ventilation (95% vs. 64%; p < 0.01), rescue therapies (ECMO) (27% vs. 12%; p = 0.106), vasopressor (95% vs. 72%; p < 0.05) and renal replacement therapy (86% vs. 30%; p < 0.001). Severity of illness was significantly higher (SAPS II: 48 (39-52) vs. 40 (32-45); p < 0.01). Patients with SLD and without presented viremic during ICU stay in 68% and 34%, respectively (p = 0.002). Occurrence of SLD was independently associated with presence of viremia [OR 6.359; 95% CI 1.336-30.253; p < 0.05] and severity of illness (SAPS II) [OR 1.078; 95% CI 1.004-1.157; p < 0.05]. Mortality was high in patients with SLD compared to other patients (68% vs. 16%, p < 0.001). After adjustment for confounders, SLD was independently associated with mortality [HR3.347; 95% CI 1.401-7.999; p < 0.01]., Conclusion: One-third of critically ill patients with COVID-19 suffer from SLD, which is associated with high mortality. Occurrence of viremia and severity of illness seem to contribute to occurrence of SLD and underline the multifactorial cause.- Published
- 2021
- Full Text
- View/download PDF
32. Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: A multicentric study in Germany.
- Author
-
Roedl K, Jarczak D, Thasler L, Bachmann M, Schulte F, Bein B, Weber CF, Schäfer U, Veit C, Hauber HP, Kopp S, Sydow K, de Weerth A, Bota M, Schreiber R, Detsch O, Rogmann JP, Frings D, Sensen B, Burdelski C, Boenisch O, Nierhaus A, de Heer G, and Kluge S
- Subjects
- Aged, Female, Germany epidemiology, Humans, Male, Middle Aged, Pneumonia, Viral virology, Retrospective Studies, SARS-CoV-2, COVID-19 mortality, COVID-19 therapy, Critical Illness, Pneumonia, Viral mortality, Pneumonia, Viral therapy, Respiration, Artificial
- Abstract
Background: There are large uncertainties with regard to the outcome of patients with coronavirus disease 2019 (COVID-19) and mechanical ventilation (MV). High mortality (50-97%) was proposed by some groups, leading to considerable uncertainties with regard to outcomes of critically ill patients with COVID-19., Objectives: The aim was to investigate the characteristics and outcomes of critically ill patients with COVID-19 requiring intensive care unit (ICU) admission and MV., Methods: A multicentre retrospective observational cohort study at 15 hospitals in Hamburg, Germany, was performed. Critically ill adult patients with COVID-19 who completed their ICU stay between February and June 2020 were included. Patient demographics, severity of illness, and ICU course were retrospectively evaluated., Results: A total of 223 critically ill patients with COVID-19 were included. The majority, 73% (n = 163), were men; the median age was 69 (interquartile range = 58-77.5) years, with 68% (n = 151) patients having at least one chronic medical condition. Their Sequential Organ Failure Assessment score was a median of 5 (3-9) points on admission. Overall, 167 (75%) patients needed MV. Noninvasive ventilation and high-flow nasal cannula were used in 31 (14%) and 26 (12%) patients, respectively. Subsequent MV, due to noninvasive ventilation/high-flow nasal cannula therapy failure, was necessary in 46 (81%) patients. Renal replacement therapy was initiated in 33% (n = 72) of patients, and owing to severe respiratory failure, extracorporeal membrane oxygenation was necessary in 9% (n = 20) of patients. Experimental antiviral therapy was used in 9% (n = 21) of patients. Complications during the ICU stay were as follows: septic shock (40%, n = 90), heart failure (8%, n = 17), and pulmonary embolism (6%, n = 14). The length of ICU stay was a median of 13 days (5-24), and the duration of MV was 15 days (8-25). The ICU mortality was 35% (n = 78) and 44% (n = 74) among mechanically ventilated patients., Conclusion: In this multicentre observational study of 223 critically ill patients with COVID-19, the survival to ICU discharge was 65%, and it was 56% among patients requiring MV. Patients showed high rate of septic complications during their ICU stay., Competing Interests: Conflict of Interest K.R., D.J., L.T., M.B., F.S., C.F.W., U.S., C.V., H.-P.H., S.Ko., K.S., A.d.W., M.B., R.S., O.D., J.-P.R., B.S., C.B., O.B., B.B., and G.d.H. do not report any conflicts of interest. S.K. received research support from Ambu, E.T.View Ltd., Fisher & Paykel, Pfizer, and Xenios; lecture honoraria from ArjoHuntleigh, Astellas, Astra, Basilea, Bard, Baxter, Biotest, CSL Behring, CytoSorbents, Fresenius, Gilead, MSD, Orion, Pfizer, Philips, Sedana, Sorin, Xenios, and Zoll; and consultant honorarium from AMOMED, Astellas, Baxter, Bayer, Fresenius, Gilead, MSD, Pfizer, and Xenios. A.N. received research funds, lecture honoraria, and travel reimbursement within the last 5 years from CytoSorbents Europe, Biotest AG, and Thermo Fisher Scientific. D.F. reports lecture honoraria within the last 5 years from Xenios AG., (Copyright © 2020 Australian College of Critical Care Nurses Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
33. The ACCOST-HH Trial.
- Author
-
Skurk C, Rottbauer W, Kessler M, Akin I, Kluge S, Burdelski C, Blankenberg S, Zeller T, Landmesser U, and Karakas M
- Published
- 2020
- Full Text
- View/download PDF
34. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.
- Author
-
Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, and Kluge S
- Subjects
- Aged, Aged, 80 and over, Betacoronavirus, COVID-19, Cause of Death, Female, Germany epidemiology, Humans, Male, Middle Aged, Pandemics, Prospective Studies, SARS-CoV-2, Tomography, X-Ray Computed, Autopsy methods, Coronavirus Infections mortality, Pneumonia, Viral mortality, Pulmonary Embolism mortality, Venous Thromboembolism mortality
- Abstract
Background: The new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused more than 210 000 deaths worldwide. However, little is known about the causes of death and the virus's pathologic features., Objective: To validate and compare clinical findings with data from medical autopsy, virtual autopsy, and virologic tests., Design: Prospective cohort study., Setting: Autopsies performed at a single academic medical center, as mandated by the German federal state of Hamburg for patients dying with a polymerase chain reaction-confirmed diagnosis of COVID-19., Patients: The first 12 consecutive COVID-19-positive deaths., Measurements: Complete autopsy, including postmortem computed tomography and histopathologic and virologic analysis, was performed. Clinical data and medical course were evaluated., Results: Median patient age was 73 years (range, 52 to 87 years), 75% of patients were male, and death occurred in the hospital ( n = 10) or outpatient sector ( n = 2). Coronary heart disease and asthma or chronic obstructive pulmonary disease were the most common comorbid conditions (50% and 25%, respectively). Autopsy revealed deep venous thrombosis in 7 of 12 patients (58%) in whom venous thromboembolism was not suspected before death; pulmonary embolism was the direct cause of death in 4 patients. Postmortem computed tomography revealed reticular infiltration of the lungs with severe bilateral, dense consolidation, whereas histomorphologically diffuse alveolar damage was seen in 8 patients. In all patients, SARS-CoV-2 RNA was detected in the lung at high concentrations; viremia in 6 of 10 and 5 of 12 patients demonstrated high viral RNA titers in the liver, kidney, or heart., Limitation: Limited sample size., Conclusion: The high incidence of thromboembolic events suggests an important role of COVID-19-induced coagulopathy. Further studies are needed to investigate the molecular mechanism and overall clinical incidence of COVID-19-related death, as well as possible therapeutic interventions to reduce it., Primary Funding Source: University Medical Center Hamburg-Eppendorf.
- Published
- 2020
- Full Text
- View/download PDF
35. Upregulation of SPDEF is associated with poor prognosis in prostate cancer.
- Author
-
Meiners J, Schulz K, Möller K, Höflmayer D, Burdelski C, Hube-Magg C, Simon R, Göbel C, Hinsch A, Reiswich V, Weidemann S, Izbicki JR, Sauter G, Jacobsen F, Möller-Koop C, Mandelkow T, Blessin NC, Lutz F, Viehweger F, Lennartz M, Fraune C, Heinzer H, Minner S, Bonk S, Huland H, Graefen M, Schlomm T, and Büscheck F
- Abstract
SAM pointed domain-containing Ets transcription factor (SPDEF), a member of the ETS transcription factor family, has been associated with prostate cancer development; however, its role in tumour development and progression is controversial. In the present study, SPDEF expression was analysed on a tissue microarray with >12,000 prostate cancer samples. SPDEF expression levels were higher in most prostate cancer samples than in normal prostate epithelium, suggesting SPDEF was upregulated in cancer. Nuclear SPDEF expression was identified in 80% of prostate cancer samples, and considered weak in 26.4%, moderate in 40.1% and strong in 13.5% of cases. SPDEF positivity was significantly associated with tumour stage, Gleason grade, lymph node metastasis and PSA recurrence (all P<0.0001). SPDEF overexpression was more common in ERG positive (94%) than in ERG negative cancer (69%; P<0.0001). Elevated SPDEF expression predicted poor prognosis independent from established prognostic parameters, including Gleason grade, pT, pN, serum PSA level and nodal status (P<0.01). In summary, SPDEF overexpression was associated with aggressive behaviour, particularly in ERG negative prostate cancer, and may have potential for clinical application., (Copyright: © Meiners et al.)
- Published
- 2019
- Full Text
- View/download PDF
36. Author Correction: Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.
- Author
-
Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, and Wilczak W
- Abstract
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.
- Published
- 2018
- Full Text
- View/download PDF
37. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues.
- Author
-
Burdelski C, Jakani-Karimi N, Jacobsen F, Möller-Koop C, Minner S, Simon R, Sauter G, Steurer S, Clauditz TS, and Wilczak W
- Subjects
- Female, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic, Humans, Male, Neoplasm Grading, Neoplasm Staging, Neoplasms metabolism, Prognosis, Neoplasms pathology, RNA-Binding Proteins metabolism, Tissue Array Analysis methods, Up-Regulation
- Abstract
IMP3 is an RNA binding protein required for ribosomal RNA processing, which has been suggested to be a prognostic marker in a large variety of human types of cancer. However, available data on the prevalence of IMP3 expression are largely discrepant. To systematically investigate the epidemiology and clinical relevance of IMP3 expression in human cancers we employed a two-step tissue microarrays (TMAs) approach. First, a normal tissue TMA and a multi-tumor TMA were analyzed for immunohistochemically detectable expression of IMP3 in 76 different normal tissue types and 3889 cancer samples from 95 different tumor categories. In a second step, we searched for associations between IMP3 expression and tumor phenotype and patient prognosis in TMAs containing 697 urinary bladder cancers, 1711 colon cancers, 343 esophageal adenocarcinomas, 251 esophageal squamous cell cancers, 673 lung cancers), 275 pancreatic cancers and 230 stomach cancers. In normal tissues, unequivocal IMP3 expression was found in placenta, lymphocytes and some types of glandular epithelial cells. In cancers, at least one case with weak expression could be found in 76 out of 95 (80%) different tumor types and 64 entities (67%) had at least one tumor with strong positivity. IMP3 expression was most frequently found in testicular cancer (including 71% seminomas and 96% non-seminomas), neuroblastoma (88%), and squamous cell cancer of various origins. Significant associations were found between IMP3 and adverse tumor features in esophageal adenocarcinomas and cancers of the urinary bladder, lung, stomach, and pancreas. In summary, IMP3 was frequently expressed in many different tumor types, and was typically associated with aggressive tumor features.
- Published
- 2018
- Full Text
- View/download PDF
38. High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.
- Author
-
Burdelski C, Shihada R, Hinsch A, Angerer A, Göbel C, Friedrich E, Hube-Magg C, Burdak-Rothkamm S, Kluth M, Simon R, Möller-Koop C, Sauter G, Büscheck F, Wittmer C, Clauditz TS, Krech T, Tsourlakis MC, Minner S, Graefen M, Schlomm T, Wilczak W, and Jacobsen F
- Subjects
- Aged, Biomarkers, Tumor biosynthesis, Humans, Immunohistochemistry, Kallikreins metabolism, Male, Middle Aged, Neoplasm Recurrence, Local enzymology, Prognosis, Prostate-Specific Antigen metabolism, Tissue Array Analysis, Lactoylglutathione Lyase biosynthesis, Prostatic Neoplasms enzymology
- Abstract
Background: Glyoxalase 1 (GLO1) is an enzyme involved in removal of toxic byproducts accumulating during glycolysis from the cell. GLO1 is up regulated in many cancer types but its role in prostate cancer is largely unknown., Methods: Here, we employed GLO1 immunohistochemistry on a tissue microarray including 11 152 tumors and an attached clinical and molecular database., Results: Normal prostate epithelium was negative for GLO1, whereas 2059 (27.3%) of 7552 interpretable cancers showed cytoplasmic GLO1 staining, which was considered weak in 8.8%, moderate in 12.5%, and strong in 6.1% of tumors. Up regulation of GLO1 was significantly linked to high original Gleason grade, advanced pathological tumor stage and positive lymph node status (P < 0.0001 each). Comparison of GLO1 staining with several common genomic alterations of prostate cancers revealed a strong link between GLO1 up regulation and TMPRSS2:ERG fusion (P < 0.0001) and an ERG-independent association with PTEN deletion (P < 0.0001). GLO1 up regulation was strongly linked to early biochemical recurrence in univariate analysis (P < 0.0001) and predicted poor prognosis independent from most (except from nodal stage) established prognostic parameters in multivariate analysis (P ≤ 0.03)., Conclusions: GLO1 upregulation is linked to aggressive prostate cancers characterized by ERG fusion and PTEN deletion. The strong and independent prognostic value makes it a promising candidate for routine diagnostic applications either alone or in combination with other markers., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
39. Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours.
- Author
-
Mills L, Drymousis P, Vashist Y, Burdelski C, Prachalias A, Srinivasan P, Menon K, Cotoi C, Khan S, Cave J, Armstrong T, Weickert MO, Izbicki J, Schrader J, Frilling A, Ramage JK, and Srirajaskanthan R
- Abstract
Small non-functioning pancreatic NETs (pNETs) ≤2 cm can pose a management dilemma in terms of surveillance or resection. There is evidence to suggest that a surveillance approach can be considered since there are no significant radiological changes observed in lesions during long-term follow-up. However, other studies have suggested loco-regional spread can be present in ≤2 cm pNETs. The aim of this study was to characterise the prevalence of malignant features and identify any useful predictive variables in a surgically resected cohort of pNETs. 418 patients with pNETs were identified from 5 NET centres. Of these 227 were included for main analysis of tumour characteristics. Mean age of patients was 57 years, 47% were female. The median follow-up was 48.2 months. Malignant features were identified in 38% of ≤2 cm pNETs. ROC analysis showed that the current cut-off of 20 mm had a sensitivity of 84% for malignancy. The rate of malignant features is in keeping with other surgical series and challenges the belief that small pNETs have a low malignant potential. This study does not support a 20 mm size cut-off as being a solitary safe parameter to exclude malignancy in pNETs., (© 2017 The authors.)
- Published
- 2017
- Full Text
- View/download PDF
40. Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers.
- Author
-
Person F, Wilczak W, Hube-Magg C, Burdelski C, Möller-Koop C, Simon R, Noriega M, Sauter G, Steurer S, Burdak-Rothkamm S, and Jacobsen F
- Subjects
- Biomarkers, Tumor biosynthesis, Gene Expression Regulation, Neoplastic, Humans, Neoplasms classification, Neoplasms pathology, Taxoids therapeutic use, Tubulin biosynthesis, Biomarkers, Tumor genetics, Neoplasms drug therapy, Neoplasms genetics, Tubulin genetics
- Abstract
Microtubules are multifunctional cytoskeletal proteins that are involved in crucial cellular roles including maintenance of cell shape, intracellular transport, meiosis, and mitosis. Class III beta-tubulin (βIII-tubulin, also known as TUBB3) is a microtubule protein, normally expressed in cells of neuronal origin. Its expression was also reported in various other tumor types, such as several types of lung cancer, ovarian cancer, and esophageal cancer. TUBB3 is of clinical relevance as overexpression has been linked to poor response to microtubule-targeting anti-cancer drugs such as taxanes. To systematically investigate the epidemiology of TUBB3 expression in normal and neoplastic tissues, we used tissue microarrays for analyzing the immunohistochemically detectable expression of TUBB3 in 3911 tissue samples from 100 different tumor categories and 76 different normal tissue types. At least 1 tumor with weak expression could be found in 93 of 100 (93%) different tumor types, and all these 93 entities also had at least 1 tumor with strong positivity. In normal tissues, a particularly strong expression was found in neurons of the brain, endothelium of blood vessels, fibroblasts, spermatogenic cells, stroma cells, endocrine cells, and acidophilic cells of the pituitary gland. In tumors, strong TUBB3 expression was most frequently found in various brain tumors (85%-100%), lung cancer (35%-80%), pancreatic adenocarcinoma (50%), renal cell carcinoma (15%-80%), and malignant melanoma (77%). In summary, these results identify a broad spectrum of cancers that can at least sporadically express TUBB3. Testing of TUBB3 in cancer types eligible for taxane-based therapies could be helpful to identify patients who might best benefit from this treatment.
- Published
- 2017
- Full Text
- View/download PDF
41. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.
- Author
-
Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, and Mills IG
- Subjects
- ATPases Associated with Diverse Cellular Activities genetics, Chromatin genetics, Chromatin pathology, DNA-Binding Proteins genetics, Humans, Male, Neoplasm Proteins genetics, Prostatic Neoplasms, Castration-Resistant genetics, Prostatic Neoplasms, Castration-Resistant pathology, Protein Serine-Threonine Kinases genetics, Receptors, Androgen genetics, Transcription Factors, ATPases Associated with Diverse Cellular Activities biosynthesis, Chromatin metabolism, Chromatin Assembly and Disassembly, DNA-Binding Proteins biosynthesis, Gene Expression Regulation, Neoplastic, Neoplasm Proteins metabolism, Prostatic Neoplasms, Castration-Resistant metabolism, Protein Serine-Threonine Kinases biosynthesis, Receptors, Androgen metabolism
- Abstract
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcription factor (TF) binding. In addition, histone acetylation readers such as bromodomain-containing protein 4 (BRD4) have been shown to associate with these TFs and contribute to aggressive cancers including prostate cancer (PC). Here, we show that chromatin accessibility defines castration-resistant prostate cancer (CRPC). We show that the deregulation of androgen receptor (AR) expression is a driver of chromatin relaxation and that AR/androgen-regulated bromodomain-containing proteins (BRDs) mediate this effect. We also report that BRDs are overexpressed in CRPCs and that ATAD2 and BRD2 have prognostic value. Finally, we developed gene stratification signature (BROMO-10) for bromodomain response and PC prognostication, to inform current and future trials with drugs targeting these processes. Our findings provide a compelling rational for combination therapy targeting bromodomains in selected patients in which BRD-mediated TF binding is enhanced or modified as cancer progresses., (Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
42. Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.
- Author
-
Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, and Wilczak W
- Abstract
Y-box binding protein 1 (YB-1) is an RNA and DNA binding factor with potential prognostic cancer. To evaluate the clinical impact of YB-1, a tissue microarray with 11,152 prostate cancers was analysed by immunohistochemistry. Cytoplasmic and nuclear staining was separately analysed. Cytoplasmic YB-1 was absent or weak in normal epithelium but seen in 86,3% of carcinomas. Cytoplasmic staining was weak, moderate, and strong in 29.6%, 43.7% and 13.0% of tumours and was accompanied by nuclear YB-1 staining in 32.1% of cases. Particularly nuclear staining was strongly linked to poor patient prognosis (p < 0.0001). YB-1 protein was more abundant in ERG positive (95.1%) than in ERG negative cancers (80.4%; p < 0.0001), but any prognostic impact of YB-1 staining was limited to the ERG-negative subset. Similarly, significant associations with pT stage and Gleason grade (p < 0.0001 each) were driven by the ERG negative subset. The significant association of YB-1 protein detection with deletions of PTEN, 5q21 and 6q15 fits well in the protein's role as an inhibitor of DNA damage dependent cell cycle arrest, a role that is likely to induce genomic instability. In summary, the data show, that the prognostic impact of YB-1 expression is limited to ERG negative prostate cancers.
- Published
- 2017
- Full Text
- View/download PDF
43. Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.
- Author
-
Burdelski C, Borcherding L, Kluth M, Hube-Magg C, Melling N, Simon R, Möller-Koop C, Weigand P, Minner S, Haese A, Michl HU, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Izbicki JR, Sauter G, Krech T, Büscheck F, Clauditz T, Schlomm T, and Wilczak W
- Subjects
- Cell Proliferation, GTPase-Activating Proteins metabolism, Genetic Variation, Humans, Immunohistochemistry, Male, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion metabolism, Prognosis, Prostatic Neoplasms pathology, Survival Analysis, Biomarkers, Tumor, GTPase-Activating Proteins genetics, Gene Expression, Prostatic Neoplasms genetics, Prostatic Neoplasms mortality
- Abstract
FAM13C, a gene with unknown function is included in several mRNA signatures for prostate cancer aggressiveness. To understand the impact of FAM13C on prognosis and its relationship to molecularly defined subsets, we analyzed FAM13C expression by immunohistochemistry on a tissue microarray containing 12,400 prostate cancer specimens. Results were compared to phenotype, ERG status, genomic deletions of 3p, 5q, 6q and PTEN, and biochemical recurrence. FAM13C was detectable in cell nuclei of cancerous and non-neoplastic prostate cells. 67.5% of 9,633 interpretable cancers showed FAM13C expression: strong in 28.3%, moderate in 24.6% and weak in 14.6%. Strong FAM13C expression was linked to advanced pT stage, high Gleason grade, positive lymph node status, and early biochemical recurrence (p < 0.0001 each). FAM13C expression was associated with TMPRSS2:ERG fusions. It was present in 85% of ERG positive but in only 54% of ERG negative cancers (p < 0.0001), and in 91.1% of PTEN deleted but in only 69.2% of PTEN non-deleted cancers (p < 0.0001). The prognostic role of FAM13C expression was independent of classical and quantitative Gleason grade, pT stage, pN stage, surgical margin status and preoperative PSA. In conclusion, the results of our study demonstrate that expression of FAM13C is an independent prognostic marker in prostate cancer. Finding FAM13C also in non-neoplastic prostate tissues highlights the importance of properly selecting cancer-rich areas for RNA-based FAM13C expression analysis.
- Published
- 2017
- Full Text
- View/download PDF
44. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
- Author
-
Burdelski C, Fitzner M, Hube-Magg C, Kluth M, Heumann A, Simon R, Krech T, Clauditz T, Büscheck F, Steurer S, Wittmer C, Hinsch A, Luebke AM, Jacobsen F, Minner S, Tsourlakis MC, Beyer B, Steuber T, Thederan I, Sauter G, Izbicki J, Schlomm T, and Wilczak W
- Subjects
- ADAM Proteins genetics, Adult, Aged, Aged, 80 and over, Disease Progression, Disintegrins metabolism, Gene Expression, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Male, Membrane Proteins genetics, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Neoplasm Staging, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion metabolism, Prognosis, Prostate-Specific Antigen, Prostatic Neoplasms genetics, Prostatic Neoplasms mortality, Sequence Deletion, Serine Endopeptidases genetics, Serine Endopeptidases metabolism, Survival Analysis, Transcriptional Regulator ERG genetics, Transcriptional Regulator ERG metabolism, ADAM Proteins metabolism, Biomarkers, Tumor, Disintegrins genetics, Membrane Proteins metabolism, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology
- Abstract
The A Disintegrin and Metalloproteinase (ADAM) family of endopeptidases plays a role in many solid cancers and includes promising targets for anticancer therapies. Deregulation of ADAM15 has been linked to tumor aggressiveness and cell line studies suggest that ADAM15 overexpression may also be implicated in prostate cancer. To evaluate the impact of ADAM15 expression and its relationship with key genomic alterations, a tissue microarray containing 12,427 prostate cancers was analyzed by immunohistochemistry. ADAM15 expression was compared to phenotype, prognosis and molecular features including TMPRSS2:ERG fusion and frequent deletions involving PTEN, 3p, 5q and 6q. Normal prostate epithelium did not show ADAM15 staining. In prostate cancers, negative, weak, moderate, and strong ADAM15 staining was found in 87.7%, 3.7%, 5.6%, and 3.0% of 9826 interpretable tumors. Strong ADAM15 staining was linked to high Gleason grade, advanced pathological tumor stage, positive nodal stage and resection margin. ADAM15 overexpression was also associated with TMPRSS2:ERG fusions and PTEN deletions (P<.0001) but unrelated to deletions of 3p, 5q and 6q. In univariate analysis, high ADAM15 expression was strongly linked to PSA recurrence (P<.0001). However, in multivariate analyses this association was only maintained if the analysis was limited to preoperatively available parameters in ERG-negative cancers. The results of our study demonstrate that ADAM15 is strongly up regulated in a small but highly aggressive fraction of prostate cancers. In these tumors, ADAM15 may represent a suitable drug target. In a preoperative scenario, ADAM15 expression measurement may assist prognosis assessment, either alone or in combination with other markers., (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
45. βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.
- Author
-
Hinsch A, Chaker A, Burdelski C, Koop C, Tsourlakis MC, Steurer S, Rink M, Eichenauer TS, Wilczak W, Wittmer C, Fisch M, Simon R, Sauter G, Büschek F, Clauditz T, Minner S, and Jacobsen F
- Subjects
- Biomarkers, Tumor genetics, Biopsy, Cell Proliferation, DNA Copy Number Variations, Gene Dosage, Genetic Predisposition to Disease, Humans, Immunohistochemistry, Neoplasm Grading, Neoplasm Staging, Phenotype, Tissue Array Analysis, Tumor Suppressor Protein p53 genetics, Up-Regulation, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology, Biomarkers, Tumor analysis, Genomic Instability, Tubulin analysis, Urinary Bladder Neoplasms chemistry
- Abstract
Development of genetic instability is a hallmark of tumor progression. Type III β-tubulin (TUBB3) is a component of microtubules involved in chromosome segregation. Its overexpression has been linked to adverse features of urinary bladder cancer. To investigate the role of TUBB3 for development of genetic instability, we compared TUBB3 expression with histopathological features and surrogate markers of genetic instability and tumor aggressiveness; copy number changes of HER2, TOP2A, CCND1, RAF1, and FGFR1; nuclear accumulation of p53, and cell proliferation in a tissue microarray (TMA) with more than 700 bladder cancers. TUBB3 expression was linked to high-grade and advanced-stage cancers (P<.0001), rapid cell proliferation (P<.0001), presence of multiple gene copy number alterations (P=.0008), and nuclear accumulation of p53 (P=.0008). Strong TUBB3 staining was found in 43% of urothelial cancers harboring copy number alterations as compared with 28% of genetically stable cancers, and in 50% of p53-positive cancers as compared with 30% of p53-negative tumors. The fraction of tumors with concomitant TUBB3 and p53 positivity increased with tumor stage and grade: 2% in pTaG1-2, 11% in pTaG3, 17% in pT1G2, 23% in pT1G3, and 32% in pT2-4 cancers (P<.0001). Importantly, strong TUBB3 overexpression was detectable in about 20% of low-grade, noninvasive cancers. In summary, our study demonstrates that TUBB3 overexpression is linked to an aggressive subtype of urinary bladder cancers, which is characterized by increased genetic instability, p53 alterations, and rapid cell proliferation. Detection of TUBB3 overexpression in genetically stable, low-grade, and noninvasive bladder cancers may be clinically useful to identify patients requiring particular close monitoring., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
46. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.
- Author
-
Burdelski C, Dieckmann T, Heumann A, Hube-Magg C, Kluth M, Beyer B, Steuber T, Pompe R, Graefen M, Simon R, Minner S, Tsourlakis MC, Koop C, Izbicki J, Sauter G, Krech T, Schlomm T, Wilczak W, and Lebok P
- Subjects
- Aged, Gene Deletion, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, PTEN Phosphohydrolase genetics, Prognosis, Prostate-Specific Antigen analysis, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Receptors, Androgen metabolism, Tissue Array Analysis methods, Transcriptional Regulator ERG metabolism, Cyclin-Dependent Kinase Inhibitor p16 metabolism, Prostatic Neoplasms metabolism, Up-Regulation
- Abstract
Altered expression of the p16 tumor suppressor is frequently found in prostate cancer, but its role for tumor development and patient prognosis is disputed. In order to clarify the prognostic role of p16 and to draw conclusions on interactions with key molecular features of prostate cancer, we studied p16 expression in a tissue microarray (TMA) with more than 12,400 prostate cancers and attached clinical, pathological, and molecular data such as ERG status and deletions of 3p13, 5q21, 6q15, and PTEN. p16 immunostaining was absent in non-neoplastic prostate cells but was found in 37 % of 9627 interpretable prostate cancers. Finding p16 expression in 58 % of ERG positive but in only 22 % of ERG negative cancers (p < 0.0001), highlights the known androgen-dependence of both genes. Significant associations between p16 upregulation and tumor phenotype or patient prognosis were strictly limited to the subset of ERG negative cancers. For example, p16 positivity increased from 15 % in Gleason ≤3 + 3 to 38 % in Gleason ≥4 + 4 cancers (p < 0.0001) and was associated with early PSA recurrence (p < 0.0001). p16 upregulation was strongly linked to deletions of PTEN (p < 0.0001), highlighting the interaction of both genes in growth control. In conclusion, p16 upregulation is a strong prognostic factor in ERG negative cancers. The strict limitation of its prognostic impact to a molecularly defined subgroup challenges the concept of molecular prognosis testing without considering molecular subtypes.
- Published
- 2016
- Full Text
- View/download PDF
47. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
- Author
-
Burdelski C, Kleinhans S, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Marx A, Sauter G, Wittmer C, Huland H, Simon R, Schlomm T, and Steurer S
- Subjects
- Adipokines, Adult, Aged, Carrier Proteins analysis, Gene Deletion, Gene Fusion, Glycoproteins analysis, Humans, Immunohistochemistry, Ki-67 Antigen analysis, Male, Middle Aged, Multivariate Analysis, PTEN Phosphohydrolase analysis, Transcriptional Regulator ERG, Carrier Proteins physiology, Glycoproteins physiology, PTEN Phosphohydrolase genetics, Prostate-Specific Antigen blood, Prostatic Neoplasms etiology, Trans-Activators genetics
- Abstract
Zinc-alpha 2-glycoprotein (AZGP1) is involved in lipid metabolism and was suggested as a candidate prognostic biomarker in prostate cancer. To evaluate the clinical impact and relationship with key genomic alterations in prostate cancer, AZGP1 expression was analyzed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancers. Data on ERG status and PTEN, 3p13, 5q21 and 6q15 deletions were available from earlier studies. AZGP1 expression was strong in benign prostatic glands but absent in 38.0% of 8,510 interpretable prostate cancers. Reduced AZGP1 expression was associated with TPMRSS2:ERG fusions, both by FISH and immunohistochemical analysis (p < 0.0001 each). For example, AZGP1 was absent in 54.6% of 2,029 ERG IHC positive but in only 28.1% of 2,398 ERG negative cancers. Irrespective of the ERG status, reduced AZGP1 expression was tightly linked to high Gleason score, advanced pathological tumor stage, positive nodal status and early PSA recurrence (p < 0.0001 each). Reduced AZGP1 expression was also strongly associated with PTEN deletions. AZGP1 immunostaining was lacking in 62.7% of 842 PTEN deleted but in only 37.3% of PTEN non-deleted cancers but retained strong prognostic influence in both subgroups (p < 0.0001 each). The prognostic role of AZGP1 expression was also independent of Gleason score, pT stage, pN stage, surgical margin status and preoperative PSA, irrespective of whether preoperative or postoperative variables were used for modeling. In conclusion, the results of our study demonstrate that reduced AZGP1 expression is strongly related to adverse prostate cancer prognosis, independently of established clinic-pathological variables and PTEN deletions., (© 2015 UICC.)
- Published
- 2016
- Full Text
- View/download PDF
48. βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma.
- Author
-
Quaas A, Rahvar AH, Burdelski C, Koop C, Eichelberg C, Rink M, Dahlem R, Schlomm T, Tsourlakis MC, Simon R, Minner S, Sauter G, and Steurer S
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Tumor biosynthesis, Carcinoma, Renal Cell diagnosis, Carcinoma, Renal Cell mortality, Female, Follow-Up Studies, Germany epidemiology, Humans, Immunohistochemistry, Kidney Neoplasms diagnosis, Kidney Neoplasms mortality, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Rate trends, Switzerland epidemiology, Carcinoma, Renal Cell metabolism, Kidney Neoplasms metabolism, Neoplasm Staging, Tubulin biosynthesis
- Abstract
Aims: βIII-tubulin (TUBB3) is a microtubule component overexpression of which is found in many solid cancer types, often linked to poor patient prognosis, and has been suggested to predict failure of microtubule-targeting chemotherapeutics. This study was designed to determine prevalence and prognostic impact of TUBB3 expression in kidney cancers., Methods and Results: A tissue microarray (TMA) containing more than 1,200 renal tumors was analyzed by immunohistochemistry. TUBB3 expression varied markedly between the different histological subtypes and was more frequent in 105 papillary cancers (75.2 %, p < 0.0001), 38 oncocytomas (52.6 %, p < 0.0001), and 22 chromophobic carcinomas (36.4 %, p = 0.1221) than in 555 clear cell RCC (16.4 %). In clear cell cancers, strong TUBB3 positivity was linked to high Fuhrman grade (p < 0.0001), advanced stage (0.002), nodal metastases (p = 0.0433), hematogenous metastases (p = 0.0016), and shortened overall survival (p < 0.0001). Associations with outcome and tumor phenotype were inversely for papillary RCC, where TUBB3 immunostaining was linked to low tumor stage (p = 0.0012) and prolonged survival (p = 0.0043)., Conclusions: TUBB3 expression levels and their effects are strikingly different between ccRCC and papillary RCC. These differences may be caused by differences in VHL function between these RCC subtypes, because VHL (like TUBB3) is another strong regulator of microtubule function.
- Published
- 2015
- Full Text
- View/download PDF
49. Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.
- Author
-
Burdelski C, Reiswich V, Hube-Magg C, Kluth M, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Huland H, Simon R, Schlomm T, Sauter G, and Steurer S
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Biomarkers, Tumor genetics, Cell Proliferation genetics, Disease-Free Survival, Gene Expression Regulation, Neoplastic, Humans, Male, Neoplasm Grading, Neoplasm Recurrence, Local pathology, PTEN Phosphohydrolase biosynthesis, PTEN Phosphohydrolase genetics, Prognosis, Prostatic Neoplasms pathology, Sequestosome-1 Protein, Tissue Array Analysis, Adaptor Proteins, Signal Transducing biosynthesis, Biomarkers, Tumor biosynthesis, Genomic Instability, Neoplasm Recurrence, Local genetics, Prostatic Neoplasms genetics
- Abstract
Purpose: Sequestosome 1 (p62) is a multifunctional adapter protein accumulating in autophagy-defective cells., Experimental Design: To evaluate the clinical impact and relationship with key genomic alterations in prostate cancer, p62 protein levels were analyzed by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Data on ERG status and deletions of PTEN, 3p13, 5q21, and 6q15 were available from earlier studies., Results: p62 immunostaining was absent in benign prostatic glands but present in 73% of 7,822 interpretable prostate cancers. Strong cytoplasmic p62 staining was tightly linked to high Gleason grade, advanced pathologic tumor (pT) stage, positive nodal status, positive resection margin, and early PSA recurrence (P < 0.0001 each). Increased levels of p62 were significantly linked to TMPRSS2-ERG fusions, both by FISH and immunohistochemical analysis (P < 0.0001 each). For example, moderate or strong p62 immunostaining was seen in 28.5% of cancers with TMPRSS2-ERG fusion detected by FISH and in 23.1% of cancers without such rearrangements (P < 0.0001). Strong p62 staining was significantly linked to the presence of all tested deletions, including PTEN (P < 0.0001), 6q15 (P < 0.0001), 5q21 (P = 0.0002), 3p13 (P = 0.0088), and 6q15 (P < 0.0001), suggesting a link between p62 accumulation and loss of genomic stability. The prognostic role of p62 protein accumulation was striking and independent of Gleason grade, pT stage, pN stage, surgical margin status, and preoperative PSA, regardless of whether preoperative or postoperative parameters were used for modeling., Conclusions: Our study identifies cytoplasmic accumulation of p62 as a strong predictor of an adverse prognostic behavior of prostate cancer independently from established clinicopathologic findings., (©2015 American Association for Cancer Research.)
- Published
- 2015
- Full Text
- View/download PDF
50. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
- Author
-
Burdelski C, Menan D, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Simon R, Schlomm T, Steurer S, and Krech T
- Subjects
- Adult, Aged, Aged, 80 and over, Cell Proliferation, Cysteine Endopeptidases, Endopeptidases metabolism, Gene Expression, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Oncogene Proteins, Fusion metabolism, Prognosis, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Serine Endopeptidases genetics, Serine Endopeptidases metabolism, Survival Analysis, Trans-Activators metabolism, Transcriptional Regulator ERG, Endopeptidases genetics, Gene Deletion, Oncogene Proteins, Fusion genetics, PTEN Phosphohydrolase genetics, Prostatic Neoplasms genetics, Prostatic Neoplasms mortality, Trans-Activators genetics
- Abstract
Background: Posttranscriptional protein modification by SUMOylation plays an important role in tumor development and progression. In the current study we analyzed prevalence and prognostic impact of the de-SUMOylation enzyme SENP1 in prostate cancer., Methods: SENP1 expression was analyzed by immunohistochemistry on a tissue microarray containing more than 12,400 prostate cancer specimens. Results were compared to tumor phenotype, ERG status, genomic deletions of 3p, 5q, 6q and PTEN, and biochemical recurrence., Results: SENP1 immunostaining was detectable in 34.5 % of 9,516 interpretable cancers and considered strong in 7.3 %, moderate in 14.9 % and weak in 12.3 % of cases. Strong SENP1 expression was linked to advanced pT stage (p < 0.0001), high Gleason grade (p < 0.0001), positive lymph node status (p = 0.0019), high pre-operative PSA levels (p = 0.0037), and PSA recurrence (p < 0.0001). SENP1 expression was strongly associated with positive ERG fusion status as determined by both in situ hybridization (FISH) and immunohistochemistry as well as with PTEN deletions. Detectable SENP1 immunostaining was found in 41 % of ERG positive and in 47 % of PTEN deleted cancers but in only 30 % of ERG negative and 30 % of PTEN non-deleted cancers (p < 0.0001 each). Deletions of 3p, 5q, and 6q were unrelated to SENP1 expression. Subset analyses revealed that the prognostic impact of SENP1 expression was solely driven by the subgroup of ERG positive, PTEN undeleted cancers. In this subgroup, the prognostic role of SENP1 expression was independent of the preoperative PSA level, tumor stage, Gleason grade, and the status of the resection margin., Conclusions: SENP1 expression has strong prognostic impact in a molecularly defined subset of cancers. This is per se not surprising as the biologic impact of each individual molecular event is likely to be dependent on its cellular environment. However, such findings challenge the concept of finding clinically relevant molecular signatures that are equally applicable to all prostate cancers.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.